[Comunicado de imprensa – ainda não publicado] Um estudo de fase 3, com mais de 10.000 participantes, mostrou que a dose de reforço com a vacina da Pfizer/BioNTech teve eficácia de 95,6% contra Covid-19; houve 5 casos de doença no grupo com dose de reforço e 109 casos no grupo-controle, sem classificação quanto à gravidade da doença.

Pfizer and BioNTech Announce Phase 3 Trial Data Showing High Efficacy of a Booster Dose of Their COVID-19 Vaccine

Comentário: Booster dose of Pfizer/BioNTech coronavirus vaccine shows 95.6% efficacy in Phase 3 trial, companies say – CNN

Comentários no Twitter

This will presumably mean everyone gets boosters early next year. That’s great, because they do work. Except it’s likely to be boosters for rich countries at the expense of primary vaccination for poorer countries. You won’t stop the pandemic when half the world is unvaccinated https://t.co/F31DMSI2zf

— Niall Conroy (@NICU_doc_salone) October 21, 2021

The 1st randomized trial of a booster (3rd) shot in 10,000 people, placebo-controlled, shows 95.6% efficacy, with 5 cases (Pfizer vaccine) vs 109 in placebo group, Delta variant, broad benefit across age groups https://t.co/TQpF35d8Jk pic.twitter.com/3RkqvXNfsU

— Eric Topol (@EricTopol) October 21, 2021